4 September 2017Americas

Inventiva and AbbVie extend agreement to develop RORγ inverse agonists

Inventiva, a biopharmaceutical company that develops innovative therapies, has announced the extension of an agreement with AbbVie to continue to research and develop orally available RORγ inverse agonists.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
3 April 2017   AbbVie has filed a declaratory judgment against Novartis, alleging that its patents covering the treatment of hepatitis C virus are invalid.
Americas
19 May 2017   AbbVie has lost in an inter partes review (IPR) of its rheumatoid arthritis drug Humira.

More on this story

Americas
3 April 2017   AbbVie has filed a declaratory judgment against Novartis, alleging that its patents covering the treatment of hepatitis C virus are invalid.
Americas
19 May 2017   AbbVie has lost in an inter partes review (IPR) of its rheumatoid arthritis drug Humira.

More on this story

Americas
3 April 2017   AbbVie has filed a declaratory judgment against Novartis, alleging that its patents covering the treatment of hepatitis C virus are invalid.
Americas
19 May 2017   AbbVie has lost in an inter partes review (IPR) of its rheumatoid arthritis drug Humira.